Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Localized gemcitabine delivery in low-grade upper tract urothelial carcinoma

Marie-Pier St-Laurent • 13 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Gemcitabine

Marie-Pier St-Laurent, MD, University of British Columbia, Vancouver, Canada, discusses the potential advantages of localized gemcitabine delivery (ST-02) for treating low-grade, non-invasive upper tract urothelial carcinoma. Unlike systemic chemotherapy or immunotherapy, this novel approach aims to prolong tumor exposure to the drug whilst minimizing systemic toxicity. Given gemcitabine’s strong safety profile in bladder cancer, this method may offer an effective and well-tolerated alternative, improving patient outcomes and quality of life. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marie-Pier St-Laurent

Balancing survival and quality of life in GU malignancies
1:40
Balancing survival and quality of life in GU malignancies
Marie-Pier St-Laurent • 13 Feb 2025
Phase II/III trial of ST-02, a mucoadhesive gemcitabine suspension, in UTUC
1:04
Phase II/III trial of ST-02, a mucoadhesive gemcitabine suspension, in UTUC
Marie-Pier St-Laurent • 14 Feb 2025
NEO-BLAST: active surveillance versus definitive therapy in MIBC
2:06
NEO-BLAST: active surveillance versus definitive therapy in MIBC
Marie-Pier St-Laurent • 13 Feb 2025
The role of urinary comprehensive genomic profiling in managing bladder cancer
1:39
The role of urinary comprehensive genomic profiling in managing bladder cancer
Marie-Pier St-Laurent • 25 Jan 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals